Published in J Steroid Biochem Mol Biol on August 01, 1994
Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer (2012) 1.20
Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci U S A (1996) 1.10
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol (2017) 1.10
Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol (2007) 1.06
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer (2015) 0.95
New insights on the role of hormonal therapy in ovarian cancer. Steroids (2013) 0.94
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res (2012) 0.91
Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. Am J Pathol (1998) 0.89
Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma. Cancer Causes Control (2008) 0.88
Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status. Am J Pathol (1998) 0.83
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br J Cancer (2013) 0.81
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res (2015) 0.79
Icb-1 gene polymorphism rs1467465 is associated with susceptibility to ovarian cancer. J Ovarian Res (2014) 0.75
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice. J Ovarian Res (2014) 0.75
Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. Ecancermedicalscience (2015) 0.75
Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens. Clin Cancer Res (2017) 0.75
Brief interventions for alcohol problems: a review. Addiction (1993) 8.64
The reliability of Form 90: an instrument for assessing alcohol treatment outcome. J Stud Alcohol (1997) 4.39
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol (2001) 4.09
Concentrations of parabens in human breast tumours. J Appl Toxicol (2004) 3.98
Estimating blood alcohol concentration: two computer programs and their applications in therapy and research. Addict Behav (1979) 3.73
Ketone-body utilization by adult and suckling rat brain in vivo. Biochem J (1971) 3.32
Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group. Lancet (1999) 2.91
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
A prognostic model for ovarian cancer. Br J Cancer (2001) 2.77
Meta-analysis of the literature on Alcoholics Anonymous: sample and study characteristics moderate findings. J Stud Alcohol (1996) 2.65
A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta (1975) 2.64
Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res (1988) 2.40
Effects of normative feedback on consumption among heavy drinking college students. J Drug Educ (1995) 2.38
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 2.37
Oestrogen receptors and breast cancer: current status. Br J Surg (1980) 2.31
Malignant melanoma in Scotland 1979-1983. Lancet (1985) 2.30
Estrogen secretion by the rat ovary in vivo during the estrous cycle and pregnancy. Endocrinology (1969) 2.25
The cost effectiveness of treatment for alcoholism: a first approximation. J Stud Alcohol (1991) 2.13
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med (2001) 2.04
Motivation for treatment: a review with special emphasis on alcoholism. Psychol Bull (1985) 2.03
Significance of aromatase activity in human breast cancer. Cancer Res (1982) 1.97
Thallium-201 SPECT imaging of brain tumors: methods and results. J Nucl Med (1990) 1.85
Reproducibility of measurements of oestrogen-receptor concentration in breast cancer. Br J Cancer (1977) 1.85
Does Alcoholics Anonymous involvement predict treatment outcome? J Subst Abuse Treat (1996) 1.81
Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer (1995) 1.81
A longitudinal model of intake symptomatology, AA participation and outcome: retrospective study of the project MATCH outpatient and aftercare samples. J Stud Alcohol (2001) 1.74
Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer (1978) 1.71
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene (1997) 1.67
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol (1998) 1.64
Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer (1996) 1.64
Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Breast Cancer Res Treat (1981) 1.64
The human tumour xenograft--a valid model in experimental chemotherapy? Br J Surg (1980) 1.63
Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab (1986) 1.62
Findings of a pilot study of motivational interviewing with pregnant drinkers. J Stud Alcohol (1999) 1.60
Focused versus broad-spectrum behavior therapy for problem drinkers. J Consult Clin Psychol (1980) 1.56
Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature (1985) 1.53
A simplified method for quantification of myocardial blood flow using nitrogen-13-ammonia and dynamic PET. J Nucl Med (1993) 1.53
Measurements of substrate uptake by mammary gland of the rat. Biochem J (1972) 1.51
Purine transport in polymorphonuclear leukocytes. Biochim Biophys Acta (1969) 1.51
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer (1996) 1.51
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol (2008) 1.50
Small-cell lung cancer after retinoblastoma. Lancet (1989) 1.48
Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer (1994) 1.48
The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol (1983) 1.47
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer (1987) 1.47
The effect of acetoacetate on plasma insulin concentration. Biochem J (1971) 1.44
The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison. Br J Cancer Suppl (1980) 1.44
Relative effectiveness of bibliotherapy, individual and group self-control training in the treatment of problem drinkers. Addict Behav (1980) 1.43
Oestrogen receptors, cellularity, elastosis and menstrual status in human breast cancer. Eur J Cancer (1978) 1.43
Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab (1993) 1.42
Dynamics of reactive oxygen intermediate production in human glioma: n-6 essential fatty acid effects. Eur J Clin Invest (1999) 1.42
Where to publish? Some considerations among English-language addiction journals. Addiction (1997) 1.42
Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol (1976) 1.41
Nipple aspirate fluid in relation to breast cancer. Breast (1999) 1.41
A human tumour model. Lancet (1986) 1.39
A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res (2000) 1.39
Noninvasive quantification of hepatic arterial blood flow with nitrogen-13-ammonia and dynamic positron emission tomography. J Nucl Med (1991) 1.38
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38
Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet (1989) 1.37
Steroid metabolism by human breast and rat mammary carcinomata. Steroids (1974) 1.36
Factor analysis for extraction of blood time-activity curves in dynamic FDG-PET studies. J Nucl Med (1995) 1.36
Internalization of Chlamydia by dendritic cells and stimulation of Chlamydia-specific T cells. J Immunol (1998) 1.35
Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med (1985) 1.34
Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clin Res Ed) (1985) 1.29
Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet (1980) 1.29
Effect of glucagon on hepatic malonyl coenzyme A concentration and on lipid synthesis. J Biol Chem (1977) 1.28
The impact of chemotherapy on small cell carcinoma of the bronchus. Q J Med (1986) 1.26
Measurement of oestradiol receptors by five institutions on common tissue samples. Br J Cancer (1978) 1.26
p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer (1990) 1.24
Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem (1999) 1.23
Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg (1989) 1.22
Atheists, agnostics and Alcoholics Anonymous. J Stud Alcohol (2002) 1.21
Inpatient alcoholism treatment. Who benefits? Am Psychol (1986) 1.21
Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer (1989) 1.20
Adenosine deaminase activity in leukaemia. Br J Cancer (1975) 1.19
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Primary systemic therapy for operable breast cancer. Br J Cancer (1991) 1.19
DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol (1993) 1.19
The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol (2005) 1.18
Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol (1999) 1.18
Bacterial osteomyelitis: findings on plain radiography, CT, MR, and scintigraphy. AJR Am J Roentgenol (1991) 1.17
Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe? Ann Oncol (2013) 1.16
Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J (Clin Res Ed) (1988) 1.16
Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr (1993) 1.15
Regional ketone body utilization by rat brain in starvation and diabetes. Am J Physiol (1986) 1.15
Oestradiol synthesis by a human breast carcinoma. Lancet (1974) 1.15
The community reinforcement approach to the treatment of substance use disorders. Am J Addict (2001) 1.15
Ketone bodies are selectively used by individual brain regions. Science (1979) 1.15
Histochemical detection of oestrogen receptors in breast carcinoma: a successful technique. Br J Cancer (1986) 1.13
Expression of oestrogen receptor beta (ERbeta1) protein in human breast cancer biopsies. Br J Cancer (2002) 1.13
Depression and learned helplessness in man. J Abnorm Psychol (1975) 1.13
Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer (1994) 1.13
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol (2001) 1.13
Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med (1992) 1.12